GLUE — Monte Rosa Therapeutics Share Price
Last trade - 00:00- $305.70m
- -$66.45m
- $75.62m
- 36
- 40
- 36
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.37 | ||
| Price to Tang. Book | 1.37 | ||
| Price to Free Cashflow | 8.04 | ||
| Price to Sales | 4.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.78% | ||
| Return on Equity | -36.15% | ||
| Operating Margin | -107.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 75.62 | 66.25 | 48 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Directors
- Alexander Mayweg NEC (46)
- Markus Warmuth PRE (50)
- Ajim Tamboli CFO (44)
- Sharon Townson CTO (46)
- Owen Wallace CSO (52)
- John Castle OTH (51)
- Filip Janku OTH (47)
- Jullian Jones OTH
- Bradley Bolzon DRC (61)
- Ali Behbahani IND (45)
- Kimberly Blackwell IND (52)
- Chandra Leo IND (51)
- Andrew Schiff IND (55)
- Christine Siu IND (44)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 21st, 2019
- Public Since
- June 24th, 2021
- No. of Shareholders
- 14
- No. of Employees
- 134
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,509,821
- Address
- 321 Harrison Avenue, Suite 900, BOSTON, 02118
- Web
- https://www.monterosatx.com/
- Phone
- +1 6179492643
- Auditors
- Deloitte & Touche LLP
Latest News for GLUE
Upcoming Events for GLUE
Q1 2025 Monte Rosa Therapeutics Inc Earnings Release
Monte Rosa Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Monte Rosa Therapeutics Inc Earnings Release
Similar to GLUE
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 22:08 UTC, shares in Monte Rosa Therapeutics are trading at $4.97. This share price information is delayed by 15 minutes.
Shares in Monte Rosa Therapeutics last closed at $4.97 and the price had moved by -11.25% over the past 365 days. In terms of relative price strength the Monte Rosa Therapeutics share price has underperformed the S&P500 Index by -19.97% over the past year.
The overall consensus recommendation for Monte Rosa Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMonte Rosa Therapeutics does not currently pay a dividend.
Monte Rosa Therapeutics does not currently pay a dividend.
Monte Rosa Therapeutics does not currently pay a dividend.
To buy shares in Monte Rosa Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.97, shares in Monte Rosa Therapeutics had a market capitalisation of $305.70m.
Here are the trading details for Monte Rosa Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GLUE
Based on an overall assessment of its quality, value and momentum Monte Rosa Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Monte Rosa Therapeutics is $16.17. That is 225.35% above the last closing price of $4.97.
Analysts covering Monte Rosa Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Monte Rosa Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -43.9%.
As of the last closing price of $4.97, shares in Monte Rosa Therapeutics were trading -19.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Monte Rosa Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Monte Rosa Therapeutics' management team is headed by:
- Alexander Mayweg - NEC
- Markus Warmuth - PRE
- Ajim Tamboli - CFO
- Sharon Townson - CTO
- Owen Wallace - CSO
- John Castle - OTH
- Filip Janku - OTH
- Jullian Jones - OTH
- Bradley Bolzon - DRC
- Ali Behbahani - IND
- Kimberly Blackwell - IND
- Chandra Leo - IND
- Andrew Schiff - IND
- Christine Siu - IND